SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    NIH. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 8390
  • 2
    Porst H. Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction. Int J Impot Res 2000; 12 (Suppl. 4): S91100
  • 3
    Pryor JL, Redmon B. New therapies and delivery mechanisms for treatment of erectile dysfunction. Int J Impot Res 2000; 12 (Suppl. 4): S15862
  • 4
    Montague DK, Jarow JP, Broderick GA et al. Chapter 1. The management of erectile dysfunction: an AUA update. J Urol 2005; 174: 2309
  • 5
    Jünemann K-P, Alken P. Pharmacotherapy of erectile dysfunction: a review. Int J Impot Res 1989; 1: 7193
  • 6
    Chen JK, Hwang TI, Yang CR. Comparison of effects following the intracorporeal injection of papaverine and prostaglandin E1. Br J Urol 1992; 69: 4047
  • 7
    Giuliano FA, Rampin O, Benoit G, Jardin A. Neural control of penile erection. Urol Clin North Am 1995; 22: 74766
  • 8
    Virag R, Frydman D, Legman M, Virag H. Intracavernous injection of papaverine as a diagnostic and therapeutic method in erectile failure. Angiology 1984; 35: 7987
  • 9
    Larsen JJ, Ottesen B, Fahrenkrug J, Fahrenkrug L. Vasoactive intestinal polypeptide (VIP) in the male genitourinary tract: concentration and motor effect. Invest Urol 1981; 19: 2113
  • 10
    Willis EA, Ottesen B, Wagner G, Sundler F, Fahrenkrug J. Vasoactive intestinal polypeptide (VIP) as a putative neurotransmitter in penile erection. Life Sci 1983; 33: 38391
  • 11
    Willis E, Ottesen B, Wagner G, Sundler F, Fahrenkrug J. Vasoactive intestinal polypeptide (VIP) as a possible neurotransmitter involved in penile erection. Acta Physiol Scand 1981; 113: 5457
  • 12
    Juenemann KP, Lue TF, Luo JA, Jadallah SA, Nunes LL, Tanagho EA. The role of vasoactive intestinal polypeptide as a neurotransmitter in canine penile erection: a combined in vivo and immunohistochemical study. J Urol 1987; 138: 8717
  • 13
    Gu J, Polak JM, Lazarides M et al. Decrease of vasoactive intestinal polypeptide (VIP) in the penises from impotent men. Lancet 1984; 2: 3158
  • 14
    Wagner G, Gerstenberg T. Intracavernosal injection of vasoactive intestinal polypeptide (VIP) does not induce erection in man per se. World J Urol 1987; 5: 1712
  • 15
    Ottesen B, Wagner G, Virag R, Fahrenkrug J. Penile erection: possible role for vasoactive intestinal polypeptide as a neurotransmitter. BMJ 1984; 288: 911
  • 16
    Roy JB, Petrone RL, Said SI. A clinical trial of intracavernous vasoactive intestinal peptide to induce penile erection. J Urol 1990; 143: 3024
  • 17
    Juenemann KP, Lue TF, Fournier GR Jr, Tanagho EA. Hemodynamics of papaverine- and phentolamine-induced penile erection. J Urol 1986; 136: 15861
  • 18
    Blum MD, Bahnson RR, Porter TN, Carter MF. Effect of local alpha-adrenergic blockade on human penile erection. J Urol 1985; 134: 47981
  • 19
    Kiely EA, Bloom SR, Williams G. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents. Br J Urol 1989; 64: 1914
  • 20
    Zentgraf M, Baccouche M, Junemann KP. Diagnosis and therapy of erectile dysfunction using papaverine and phentolamine. Urol Int 1988; 43: 6575
  • 21
    Gerstenberg TC, Metz P, Ottesen B, Fahrenkrug J. Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure. J Urol 1992; 147: 12779
  • 22
    Dinsmore WW, Alderdice DK. Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents. Br J Urol 1998; 81: 43740
  • 23
    Dinsmore WW, Gingell C, Hackett G et al. Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study. BJU Int 1999; 83: 2749
  • 24
    Hackett G, Larsen F. Clinical experience with Invicorp at Good Hope Hospital ED Clinic, 1996–2006. J Sex Med 2007; 4: 134
  • 25
    Sandhu D, Curless E, Dean J et al. A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phenotolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction. Int J Impot Res 1999; 11: 917
  • 26
    McMahon CG. A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction. Int J Impot Res 1996; 8: 2336
  • 27
    Kim N. Potentiation of VIP-induced relaxation by phentolamine in corpus cavernosum. Int J Imp Res 1998; 10: A327
  • 28
    Committee for Proprietary Medicinal Products. Note for guidance on Fixed Combination Medicinal Products. Cited; CPMP/CWP240/95:1996 Available at: http://www.emea.europa.eu/pdfs/human/ewp/024095en.pdf. Accessed March 2008
  • 29
    Keijzers GB. Aviptadil (Senatek). Curr Opin Invest Drugs 2001; 2: 5459
  • 30
    Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996; 155: 80215
  • 31
    Gerstenberg T. Long term use of vasopotin in the treatment of erectile dysfunction. Int J Imp Res 1995; 7: S5
  • 32
    Shah PJ, Dinsmore W, Oakes RA, Hackett G. Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate. Curr Med Res Opin 2007; 23: 257783
  • 33
    Junemann KP, Manning M, Krautschick A, Alken P. 15 years of injection therapy in erectile dysfunction: a review. Int J Imp Res 1996; 8: A60
  • 34
    Porst H, Buvat J, Meuleman E, Michal V, Wagner G. Final results of a prospective multicenter-study with self-injection therapy with PGE1 after 4 years of follow-up. Int J Imp Res 1996; 8: D118
  • 35
    Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group N Engl J Med 1996; 334: 8737